11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Quantitative assessment of radiation dose and fractionation effects on normal tissue by utilizing a novel lung fibrosis index model

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Normal lung tissue tolerance constitutes a limiting factor in delivering the required dose of radiotherapy to cure thoracic and chest wall malignancies. Radiation-induced lung fibrosis (RILF) is considered a critical determinant for late normal tissue complications. While RILF mouse models are frequently approached e.g., as a single high dose thoracic irradiation to investigate lung fibrosis and candidate modulators, a systematic radiobiological characterization of RILF mouse model is urgently needed to compare relative biological effectiveness (RBE) of particle irradiation with protons, helium-, carbon and oxygen ions now available at HIT. We aimed to study the dose-response relationship and fractionation effect of photon irradiation in development of pulmonary fibrosis in C57BL/6 mouse.

          Methods

          Lung fibrosis was evaluated 24 weeks after single and fractionated whole thoracic irradiation by quantitative assessment of lung alterations using CT. The fibrosis index ( FI) was determined based on 3D-segmentation of the lungs considering the two key fibrosis parameters affected by ionizing radiation i.e., a dose/fractionation dependent reduction of the total lung volume and increase of the mean lung density.

          Results

          The effective dose required to induce 50% of the maximal possible fibrosis ( ED 50 ) was 14.55 ± 0.34Gy and 27.7 ± 1.22Gy, for single and five- fractions irradiation, respectively. Applying a deterministic model an α/β = 4.49 ± 0.38 Gy for the late lung radiosensitivity was determined. Intriguingly, we found that a linear-quadratic model could be applied to in-vivo log transformed fibrosis ( FI) vs. irradiation doses. The LQ model revealed an α/β for lung radiosensitivity of 4.4879 Gy for single fraction and 3.9474 for 5-fractions. Our FI based data were in good agreement with a meta-analysis of previous lung radiosensitivity data derived from different clinical endpoints and various mouse strains. The effect of fractionation on RILF development was further estimated by the biologically effective dose (BED) model with threshold BED ( BED Tr ) = 30.33 Gy and BED ED50  = 61.63 Gy, respectively.

          Conclusion

          The systematic radiobiological characterization of RILF in the C57BL/6 mouse reported in this study marks an important step towards precise estimation of dose-response for development of lung fibrosis. These radiobiological parameters combined with a large repertoire of genetically engineered C57BL/6 mouse models, build a solid foundation for further biologically individualized risk assessment of RILF and functional RBE prediction on novel of particle qualities.

          Electronic supplementary material

          The online version of this article (10.1186/s13014-017-0912-y) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references38

          • Record: found
          • Abstract: found
          • Article: not found

          Animal models of fibrotic lung disease.

          Interstitial lung fibrosis can develop as a consequence of occupational or medical exposure, as a result of genetic defects, and after trauma or acute lung injury leading to fibroproliferative acute respiratory distress syndrome, or it can develop in an idiopathic manner. The pathogenesis of each form of lung fibrosis remains poorly understood. They each result in a progressive loss of lung function with increasing dyspnea, and most forms ultimately result in mortality. To better understand the pathogenesis of lung fibrotic disorders, multiple animal models have been developed. This review summarizes the common and emerging models of lung fibrosis to highlight their usefulness in understanding the cell-cell and soluble mediator interactions that drive fibrotic responses. Recent advances have allowed for the development of models to study targeted injuries of Type II alveolar epithelial cells, fibroblastic autonomous effects, and targeted genetic defects. Repetitive dosing in some models has more closely mimicked the pathology of human fibrotic lung disease. We also have a much better understanding of the fact that the aged lung has increased susceptibility to fibrosis. Each of the models reviewed in this report offers a powerful tool for studying some aspect of fibrotic lung disease.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis

            Pulmonary fibrosis is the consequence of a variety of diseases with no satisfying treatment option. Therapy-induced fibrosis also limits the efficacy of chemotherapy and radiotherapy in numerous cancers. Here, we studied the potential of platelet-derived growth factor (PDGF) receptor tyrosine kinase inhibitors (RTKIs) to attenuate radiation-induced pulmonary fibrosis. Thoraces of C57BL/6 mice were irradiated (20 Gy), and mice were treated with three distinct PDGF RTKIs (SU9518, SU11657, or Imatinib). Irradiation was found to induce severe lung fibrosis resulting in dramatically reduced mouse survival. Treatment with PDGF RTKIs markedly attenuated the development of pulmonary fibrosis in excellent correlation with clinical, histological, and computed tomography results. Importantly, RTKIs also prolonged the life span of irradiated mice. We found that radiation up-regulated expression of PDGF (A–D) isoforms leading to phosphorylation of PDGF receptor, which was strongly inhibited by RTKIs. Our findings suggest a pivotal role of PDGF signaling in the pathogenesis of pulmonary fibrosis and indicate that inhibition of fibrogenesis, rather than inflammation, is critical to antifibrotic treatment. This study points the way to a potential new approach for treating idiopathic or therapy-related forms of lung fibrosis.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Tumour and normal tissue responses to fractionated non-uniform dose delivery.

              The dose-volume response of tumours and normal tissues is discussed in terms of 'parallelity' and 'seriality'. The volume dependence of the radiation response of a tumour depends primarily on the eradication of all its clonogenic cells and the tumour has a parallel organization. The response of heterogeneous tumours is examined, and it is shown that a small resistant clonogen population may cause a low dose-response gradient, gamma. Injury to normal tissue is a much more complex and gradual process. It depends on earlier effects induced long before depletion of stem cells or differentiated cells that in addition may have a complex structural and functional organization. The volume dependence of the dose-response relation of normal tissues is therefore described here by a new parameter, the 'relative seriality', s, of the infrastructure of the organ. The model is compared with clinical and experimental data on normal tissue response, and shows good agreement both with regard to the shape of dose-response relation and the volume dependence of the isoeffect dose. For example, the spinal cord has a high and the lung a low 'relative seriality', which is reasonable with regard to the organization of these tissues. The response of tumours and normal tissues to non-uniform dose delivery is quantified for fractionated therapy using the linear quadratic cell survival parameters alpha and beta. The steepness, gamma, and the 50% response dose, D50, of the dose-response relationship are derived both for a constant dose per fraction and a constant number of dose fractions.
                Bookmark

                Author and article information

                Contributors
                +49 6221 56 39604 , c.zhou@dkfz-Heidelberg.de
                bleddyn.jones@oncology.ox.ac.uk
                m.moustafa@dkfz-Heidelberg.de
                C.Schwager@dkfz-heidelberg.de
                Julia.Bauer@med.uni-heidelberg.de
                bing@physi.uni-heidelberg.de
                caoliji@gmail.com
                m.jia@dkfz-heidelberg.de
                andrea.mairani@googlemail.com
                chenming@zjcc.org.cn
                c.offoo@gmail.com
                juergen.debus@med.uni-heidelberg.de
                a.amir@dkfz-Heidelberg.de
                Journal
                Radiat Oncol
                Radiat Oncol
                Radiation Oncology (London, England)
                BioMed Central (London )
                1748-717X
                7 November 2017
                7 November 2017
                2017
                : 12
                : 172
                Affiliations
                [1 ]ISNI 0000 0001 0328 4908, GRID grid.5253.1, German Cancer Consortium (DKTK), Translational Radiation Oncology, , National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), ; INF 460, 69120 Heidelberg, Germany
                [2 ]ISNI 0000 0001 2190 4373, GRID grid.7700.0, Department of Radiation Oncology, Heidelberg Ion-Beam Therapy Centre (HIT), , University of Heidelberg Medical School, ; Heidelberg, Germany
                [3 ]Heidelberg Institute of Radiation Oncology (HIRO), National Center for Radiation research in Oncology (NCRO), Heidelberg, Germany
                [4 ]Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China
                [5 ]ISNI 0000 0004 1936 8948, GRID grid.4991.5, Gray Laboratory, CRUK/MRC Oxford Oncology Institute, Radiation Oncology, , University of Oxford, ; Oxford, UK
                [6 ]ISNI 0000 0000 9889 5690, GRID grid.33003.33, Department of Clinical Pathology, , Suez Canal University, ; Ismailia, Egypt
                [7 ]ISNI 0000 0001 2190 4373, GRID grid.7700.0, Physics Institute University of Heidelberg, ; Heidelberg, Germany
                [8 ]Inviscan SAS, Strasbourg, France
                [9 ]ISNI 0000 0004 0492 0584, GRID grid.7497.d, Division of Clinical Epidemiology and Aging Research, , German Cancer Research Center (DKFZ), ; Heidelberg, Germany
                [10 ]ISNI 0000 0004 1808 0985, GRID grid.417397.f, Zhejiang Key Lab of Radiation Oncology, , Zhejiang Cancer Hospital, ; Hangzhou, China
                [11 ]Italian National Center for Oncological Hadron Therapy (CNAO), Pavia, Italy
                Article
                912
                10.1186/s13014-017-0912-y
                5678815
                29116014
                e76464be-0ef1-4b7d-86ae-3353c6c8766e
                © The Author(s). 2017

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 16 August 2017
                : 27 October 2017
                Funding
                Funded by: NSFC
                Award ID: No. 81703166/H2201
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100001659, Deutsche Forschungsgemeinschaft;
                Award ID: KFO214
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100005972, Deutsche Krebshilfe;
                Award ID: Max-Eder 108876
                Award Recipient :
                Funded by: National Center for Tumor diseases
                Award ID: NCT 3.0-2015.22 BioDose and DKTK/DKFZ
                Award Recipient :
                Categories
                Research
                Custom metadata
                © The Author(s) 2017

                Oncology & Radiotherapy
                thoracic radiotherapy,lung fibrosis,fractionation,bed,α/β ratio
                Oncology & Radiotherapy
                thoracic radiotherapy, lung fibrosis, fractionation, bed, α/β ratio

                Comments

                Comment on this article